Nontuberculous Mycobacteria Market

Rising Rates of Infectious Illnesses is Driving the Market Growth

This is because increased awareness of NTM infections can lead to early detection and more frequent diagnostic testing, more research and development efforts for NTM treatments, and a greater demand for therapies that target NTM pathogens as a result of increased attention to infectious diseases in healthcare. For instance, as of December 2022, the United Nations International Children's Emergency Fund (UNICEF) stated that the most common infectious disease killing over 700,000 children annually—roughly 2,000 children every day—was pneumonia. Consequently, the market for nontuberculous mycobacterial is expanding because to the rising incidence of infectious disorders.

The market for nontuberculous mycobacterial is anticipated to rise in the future due to the increasing frequency of chronic obstructive pulmonary disease (COPD). The long-term and frequently worsening restriction of lung airflow is the hallmark of chronic obstructive pulmonary disease (COPD), a chronic respiratory illness. Patients with COPD who have nontuberculous mycobacterial (NTM) had a higher exacerbation rate and a more marked drop in their forced expiratory volume in one second (FEV1). 

The immune system may be weakened and lung tissue may be damaged by COPD, which increases the likelihood that NTM bacteria will infect the lungs. For instance, in March 2023, COPD rates started to rise between 2021 and 2022, with male rates rising from 83.2 to 97.6 per 100,000 people and female rates rising from 72.6 to 97.3, per a report released by The Scottish Public Health Observatory (ScotPHO), a public health organization based in Scotland. Therefore, the market for nontuberculous mycobacterial is growing as a result of the increased prevalence of chronic obstructive pulmonary disease (COPD).

Moreover, to maintain their market position, major players in the nontuberculous mycobacterial market implement new treatment approval procedures. For instance, in June 2021, the US-based pharmaceutical company Paratek Pharmaceuticals Inc. was granted permission to broaden the indication for NUZYRA (omadacycline) in the treatment of adult community-acquired bacterial pneumonia (CABP). In order to combat tetracycline resistance, NUZYRA is a modified tetracycline that works against a variety of bacteria, including atypical strains, drug-resistant strains, Gram-positive and Gram-negative bacteria.

Furthermore, in July 2022, NUZYRA was given Fast Track designation by the US federal agency Food and Drug Administration to treat nontuberculous mycobacterial (NTM) lung disease caused by MAC (Mycobacterium avium complex). Thus, driving the Nontuberculous Mycobacteria market revenue.

The Global Nontuberculous Mycobacteria Market Industry is projected to experience steady growth, with estimates indicating a market value of 9.35 USD Billion in 2024 and a potential increase to 12.3 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 2.5% from 2025 to 2035, reflecting the ongoing demand for effective diagnostic and therapeutic solutions. The market's expansion is likely influenced by various factors, including advancements in medical technology, increased awareness of nontuberculous mycobacterial infections, and the rising prevalence of respiratory diseases. These projections underscore the importance of continued investment in research and healthcare resources.

The demographic shift towards an aging population globally is anticipated to impact the Global Nontuberculous Mycobacteria Market Industry significantly. Older adults are generally more susceptible to infections, including those caused by nontuberculous mycobacteria. As the global population aged 65 and older continues to grow, the demand for effective treatment and management options is likely to increase. This trend may drive healthcare investments and research focused on this demographic, thereby enhancing market growth. The implications of this demographic change are profound, as it suggests a sustained need for healthcare resources dedicated to addressing infections in older populations.

Technological innovations in diagnostic methods for nontuberculous mycobacteria are poised to enhance the Global Nontuberculous Mycobacteria Market Industry. The development of rapid molecular tests and advanced imaging techniques facilitates earlier and more accurate detection of infections. These advancements not only improve patient outcomes but also drive market growth as healthcare providers seek efficient diagnostic solutions. The integration of these technologies into clinical practice is expected to contribute to the market's expansion, with a projected compound annual growth rate of 2.5% from 2025 to 2035, reflecting the ongoing evolution in diagnostic capabilities.

Increased awareness and educational initiatives regarding nontuberculous mycobacterial infections are likely to propel the Global Nontuberculous Mycobacteria Market Industry. Public health campaigns and professional training programs aim to inform both healthcare providers and patients about the risks and management of these infections. As knowledge spreads, the likelihood of early diagnosis and treatment increases, potentially reducing morbidity associated with these conditions. This heightened awareness is expected to contribute to the market's growth trajectory, with estimates suggesting a market value of 12.3 USD Billion by 2035, underscoring the importance of education in addressing this public health concern.

Ongoing research and development activities focused on nontuberculous mycobacteria are expected to foster innovation within the Global Nontuberculous Mycobacteria Market Industry. Pharmaceutical companies and research institutions are increasingly investing in the discovery of novel therapeutics and vaccines aimed at combating these infections. This focus on R&D not only aims to improve treatment efficacy but also addresses the growing concern of antibiotic resistance. As new products enter the market, they may reshape treatment paradigms and enhance patient care, thereby contributing to the overall market growth in the coming years.

The rising incidence of respiratory diseases globally appears to be a significant driver for the Global Nontuberculous Mycobacteria Market Industry. Conditions such as chronic obstructive pulmonary disease and asthma are becoming more prevalent, leading to a heightened awareness and diagnosis of nontuberculous mycobacterial infections. As healthcare systems increasingly recognize the impact of these infections, the demand for diagnostic tools and treatment options is likely to grow. This trend is reflected in the projected market value of 9.35 USD Billion in 2024, indicating a robust response to the increasing burden of respiratory ailments.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Nontuberculous Mycobacteria market area will dominate this market because infections with nontuberculous mycobacterium are so common. The existence of large pharmaceutical corporations, rising research efforts for the creation of new pharmaceuticals, and high healthcare costs are all predicted to contribute to the market's expansion.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: Nontuberculous Mycobacteria Market Share By Region 2022 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe Nontuberculous Mycobacteria market accounts for the second-largest market share. This industry offers a plethora of chances as more individuals prefer short-term, very effective therapies. Spending by healthcare departments will drive market expansion. The European Medicines Agency is now marketing ARIKACE, an inhalation medication used to treat nontuberculous mycobacterium, as an orphan drug. Further, the German Nontuberculous Mycobacteria market held the largest market share, and the UK Nontuberculous Mycobacteria market was the fastest growing market in the European region

The Asia-Pacific Nontuberculous Mycobacteria Market is expected to grow at the fastest CAGR from 2023 to 2032. The rising prevalence of NTM infections in Asia Pacific, particularly in individuals with compromised immune systems or underlying respiratory conditions, is a significant contributing cause. This area has a sophisticated healthcare infrastructure and a robust pharmaceutical sector in addition to cutting-edge diagnostic capabilities. Moreover, China’s Nontuberculous Mycobacteria market held the largest market share, and the Indian Nontuberculous Mycobacteria market was the fastest growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Nontuberculous Mycobacteria market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Nontuberculous Mycobacteria industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Nontuberculous Mycobacteria industry to benefit clients and increase the market sector. In recent years, the Nontuberculous Mycobacteria industry has offered some of the most significant advantages to medicine. Major players in the Nontuberculous Mycobacteria market are attempting to increase market demand by investing in research and development operations includes Insmed, Paratek Pharmaceuticals Inc, RedHill Biopharma Ltd, Janssen, Novartis AG, RevImmune, and Nobelpharma Co Ltd.

RedHill Biopharma Ltd (RedHill) is a specialized biopharmaceutical business that creates and markets treatments for cancer and gastrointestinal (GI) disorders. The commercial product portfolio of the company include branded prescription medications, such as a combination of omeprazole, amoxicillin, and rifabutin; naloxegol; and rifamycin. For the treatment of Crohn's disease, non-tuberculous mycobacterial infections (NTM) infections, irritable bowel syndrome with diarrhea (IBS-D), gastroenteritis, bowel cleanser, gastritis, cancer, and novel coronavirus disease (COVID-19), RedHill is researching its pipeline candidates.

A multinational biopharmaceutical business called Insmed is dedicated to improving the lives of people suffering from severe and uncommon illnesses. In addition to aiming to comprehend and improve the full patient experience—from diagnosis and treatment to day-to-day living—the company is committed to creating and introducing medicines that truly improve the lives of its patients. It is a quickly expanding firm with locations throughout seven countries, and its headquarters are in Bridgewater, NJ.